Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of pyrotinib versus docetaxel after platinum chemotherapy failure in advanced non-squamous non-small cell lung cancer
CTR20201351Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pyrotinib, docetaxel in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Sep 2020; status: completed.
02
Drugs
pyrotinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20201351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201351.